WallStreetZenWallStreetZen

NYSEMKT: CATX
Perspective Therapeutics Revenue

OverviewForecastEarningsRevenue
DividendOwnership
Perspective Therapeutics revenue was $1.24M for the trailing 12 months ending Jun 30, 2025, with N/A growth year over year. Quarterly revenue for the quarter (Q2 2025) ending on Jun 30, 2025 was $290.0k, down 15.2% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, CATX annual revenue was $1.5M, with 1.4% growth year-over-year.

CATX past revenue growth

How has CATX's revenue growth performed historically?

Company
-15.64%
Industry
11.06%
Market
20.47%
CATX's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
CATX's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance
CATX's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

CATX revenue history

Current Revenue
$1.2M
Current Earnings
-$95.0M
Current Profit Margin
-7,688.5%

Be the first to know when CATX announces revenue.

CATX Revenue History By Year

CATX Yearly RevenueCATX RevenueCATX ChangeCATX Revenue Growth
2024-12-31$1.45M$20.00k+1.39%
2023-12-31$1.43MN/AN/A
2022-06-30$0.00-$10.05M-100.00%
2021-06-30$10.05M$373.00k+3.85%
2020-06-30$9.68M$2.37M+32.35%
2019-06-30$7.31M$1.39M+23.48%
2018-06-30$5.92M$1.16M+24.41%
2017-06-30$4.76M-$8.00k-0.17%
2016-06-30$4.77M$163.00k+3.54%
2015-06-30$4.61M$386.84k+9.17%
2014-06-30$4.22M-$306.08k-6.76%
2013-06-30$4.53M-$545.86k-10.76%
2012-06-30$5.07M-$167.89k-3.20%
2011-06-30$5.24M-$47.11k-0.89%
2010-06-30$5.29M-$131.73k-2.43%
2009-06-30$5.42M-$1.74M-24.32%
2008-06-30$7.16M$1.42M+24.76%
2007-06-30$5.74M$3.74M+187.72%
2006-06-30$1.99M$1.79M+888.60%
2005-06-30$201.73kN/AN/A
2004-09-30$0.00N/AN/A
2003-09-30$0.00N/AN/A

1 of 2

Perspective Therapeutics Revenue FAQ

What was CATX's revenue last quarter?

On Invalid Date, Perspective Therapeutics (NYSEMKT: CATX) reported Q2 2025 revenue of $290.00 thousand up 44.87% year over year. In the same quarter last year, Perspective Therapeutics's revenue was $526.00 thousand.

What was Perspective Therapeutics's revenue in 2024?

Perspective Therapeutics's annual revenue for the twelve months ending Dec 31, 2024 was $1.45 million, a 1.39% increase year over year.

How much does Perspective Therapeutics make in a day?

Based on Perspective Therapeutics annual revenue for the past five years, CATX makes an average of $12,395.07 per day.

What was Perspective Therapeutics's annual revenue growth in the past year?

As of Q4 2025, Perspective Therapeutics's revenue has grown -15.64% year over year. This is 26.7 percentage points lower than the US Medical Devices industry revenue growth rate of 11.06%. Perspective Therapeutics's revenue in the past year totaled $1.24 million.

How much does Perspective Therapeutics make in a year?

Perspective Therapeutics's revenue by year for the past five years is:
  • Perspective Therapeutics's revenue for the twelve months ending Dec 31, 2024 was $1.45 million, a 1.39% increase year over year.
  • Perspective Therapeutics's annual revenue for Dec 31, 2023 was $1.43 million, a Infinity% increase from 2022.
  • Perspective Therapeutics's annual revenue for 2022 was $0.00, a 100% decrease from 2021.
  • Perspective Therapeutics's annual revenue for 2021 was $10.05 million, a 3.85% increase from 2020.
  • Perspective Therapeutics's annual revenue for 2020 was $9.68 million, a 32.35% increase from 2019.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.